The Treatment Window
For most LCA genes, timing can matter as much as the therapy itself. Here is why — and why getting an exact genetic diagnosis early can be decisive.
Today's gene therapies work by adding or repairing a gene inside photoreceptors — the eye's light-sensing cells. They can only help cells that are still alive.
So there is a window of opportunity: while enough photoreceptors survive, treatment can preserve — and sometimes restore — vision. Once those cells are gone, adding a gene can no longer bring them back.
How long the window stays open differs from gene to gene. Finding out your exact gene early is how you learn whether yours is still open.
How the window differs by gene
Drag the age slider to see where each gene's window typically sits at that age.
Illustrative and population-level, drawn from each subtype's natural history — not a prediction for any individual. The bars show roughly how long salvageable photoreceptors tend to remain; individual courses vary widely.
Photoreceptors stay structurally intact for years, giving an unusually wide window — ATSN-101 improved vision even in treated adults.
A rapid early decline is followed by long stabilization, with macular structure often preserved into adulthood.
The fundus can look near-normal in infancy and residual outer-retinal structure often persists into the fourth decade — but severity varies widely.
Residual cone-mediated vision through roughly the first three decades, declining thereafter — earlier treatment tends to preserve more.
Severe from early childhood, yet central (foveal) cones can persist for decades; teenagers responded better than adults in trials.
A highly variable course — some retinal structure is preserved, but presentations range from LCA to milder dystrophy.
Early macular atrophy with marked progression through adolescence — a comparatively narrow window.
One of the most severe forms: the outer retina is relatively preserved only before about age 4, so treatment must come very early.
Why this is changing: finding it before vision is lost
The biggest lever on the treatment window is diagnosing earlier. Newborn genome-sequencing programs — such as Genomics England's Generation Study, screening 100,000 babies for hundreds of treatable conditions, with the NHS planning a wider rollout — can identify treatable inherited blindness before symptoms appear. That can turn “diagnosed after vision is lost” into “treated while the window is still open.”
Genomics England — Generation StudyThis page is a simplified, educational guide, not medical advice or a personal prognosis. Windows are population-level generalizations; individual disease varies with the exact mutation, and only your retinal specialist can assess your window with a genetic diagnosis and OCT imaging. And a “closing” window is not the end of hope — approaches such as optogenetics and cell replacement are being developed precisely for when photoreceptors are already lost.
Background: gene therapies for inherited retinal diseases (Retinal Physician, 2025)Find out where your gene stands
An exact genetic diagnosis is the first step. See each LCA subtype and how far treatment has advanced, or follow the whole path from lab to patient.